Astellas gains full control of Maxygen joint venture Perseid
This article was originally published in Scrip
In line with a 2009 agreement, Astellas has now completed the exercise of an option to acquire all of Maxygen's shareholding in the Perseid Therapeutics US joint venture, paying $76 million in cash to make the research operation a wholly owned subsidiary.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.